{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:00:02Z","timestamp":1783645202984,"version":"3.55.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"DOI":"10.1210\/jcem.87.4.8373","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T17:08:03Z","timestamp":1389200883000},"page":"1521-1526","source":"Crossref","is-referenced-by-count":75,"title":["Lack of Impact of Radioiodine Therapy in Tg-Positive, Diagnostic Whole-Body Scan-Negative Patients with Follicular Cell-Derived Thyroid Cancer"],"prefix":"10.1210","volume":"87","author":[{"given":"Vahab","family":"Fatourechi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (V.F., I.D.H., C.A.G.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Hay","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (V.F., I.D.H., C.A.G.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houman","family":"Javedan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Section of Nuclear Medicine (G.A.W., B.P.M.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Mullan","sequence":"additional","affiliation":[{"name":"Section of Nuclear Medicine (G.A.W., B.P.M.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colum A.","family":"Gorman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, Nutrition, and Internal Medicine (V.F., I.D.H., C.A.G.), Mayo Clinic, Rochester, Minnesota 55905"},{"name":"Department of Health Sciences Research (C.A.G.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113233292800_R1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM197908093010605","article-title":"Control of thyroglobulin synthesis and secretion (second of two parts)","volume":"301","author":"Van Herle","year":"1979","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113233292800_R2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1172\/JCI107303","article-title":"Radioimmunoassay for measurement of thyroglobulin in human serum","volume":"52","author":"Van Herle","year":"1973","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t2019041113233292800_R3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0889-8529(18)30023-9","article-title":"Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls","volume":"24","author":"Spencer","year":"1995","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key\n\t\t\t\t2019041113233292800_R4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/eje.0.1380249","article-title":"Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma","volume":"138","author":"Schlumberger","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113233292800_R5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0001-2998(97)80045-1","article-title":"The changing role of radioiodine in the management of differentiated thyroid cancer","volume":"27","author":"Reynolds","year":"1997","journal-title":"Semin Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1089\/thy.1996.6.485","article-title":"Nuclear imaging in the management of thyroid carcinoma","volume":"6","author":"Cavalieri","year":"1996","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R7","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJM199709253371304","article-title":"Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma","volume":"337","author":"Ladenson","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113233292800_R8","first-page":"3877","article-title":"A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer","volume":"84","author":"Haugen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/nm.2000.4600","article-title":"Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance","volume":"30","author":"Fatourechi","year":"2000","journal-title":"Semin Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/thy.1998.8.63","article-title":"Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50","volume":"8","author":"Venkataraman","year":"1998","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R11","first-page":"92","article-title":"Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers","volume":"20","author":"Nemec","year":"1979","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/thy.2000.10.573","article-title":"Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?","volume":"10","author":"Fatourechi","year":"2000","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R13","first-page":"629","article-title":"Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma","volume":"78","author":"Sherman","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R14","first-page":"1888","article-title":"Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels","volume":"28","author":"Pacini","year":"1987","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R15","first-page":"1488","article-title":"Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan","volume":"80","author":"Pineda","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.1997.7.273","article-title":"131I therapy for elevated thyroglobulin levels","volume":"7","author":"Schlumberger","year":"1997","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R17","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/0959-8049(96)00020-2","article-title":"Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease","volume":"32A","author":"Tenenbaum","year":"1996","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019041113233292800_R18","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1210\/jcem.83.12.5293-1","article-title":"The use of radioactive iodine in patients with papillary and follicular thyroid cancer","volume":"83","author":"Wartofsky","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R19","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/thy.1994.4.501","article-title":"Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans","volume":"4","author":"Clark","year":"1994","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1089\/thy.1997.7.669","article-title":"131I treatment of 131I negative whole body scan, and positive thyroglobulin in differentiated thyroid carcinoma: what is being treated?","volume":"7","author":"McDougall","year":"1997","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jcem.80.5.7744990","article-title":"Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark?","volume":"80","author":"Mazzaferri","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R22","first-page":"3228","article-title":"Expression of the Na+\/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes","volume":"84","author":"Lazar","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R23","first-page":"2493","article-title":"Iodide symporter gene expression in human thyroid tumors","volume":"83","author":"Arturi","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/thy.1997.7.277","article-title":"Detection of thyroid remnant\/metastasis without stunning: an ongoing dilemma","volume":"7","author":"Park","year":"1997","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R25","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1210\/jcem.86.8.7717","article-title":"The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals","volume":"86","author":"Morris","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113233292800_R27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1210\/jcem.82.1.3696","article-title":"Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone","volume":"82","author":"Rudavsky","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R28","first-page":"257","article-title":"Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma","volume":"35","author":"Lubin","year":"1994","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R29","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/thy.2000.10.975","article-title":"Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy","volume":"10","author":"Sera","year":"2000","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R30","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/thy.2000.10.971","article-title":"The risks and benefits of radioiodine therapy for thyroid carcinoma remain somewhat undifferentiated","volume":"10","author":"Haugen","year":"2000","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113233292800_R31","first-page":"1790","article-title":"Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays","volume":"29","author":"Schlumberger","year":"1988","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041113233292800_R32","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/jcem.86.9.7831","article-title":"Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients","volume":"86","author":"Pacini","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jcem.86.4.7407","article-title":"Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113233292800_R34","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1210\/jcem.86.8.7719","article-title":"131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study","volume":"86","author":"Ceccarelli","year":"2001","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/4\/1521\/10403255\/jcem1521.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T00:52:55Z","timestamp":1565052775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/87\/4\/1521\/2374938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":34,"aliases":["10.1210\/jc.87.4.1521"],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcem.87.4.8373","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4,1]]}}}